BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31719101)

  • 1. Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts.
    Shin SJ; Dodd-Eaton EB; Peng G; Bojadzieva J; Chen J; Amos CI; Frone MN; Khincha PP; Mai PL; Savage SA; Ballinger ML; Thomas DM; Yuan Y; Strong LC; Wang W
    Cancer Res; 2020 Jan; 80(2):354-360. PubMed ID: 31719101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.
    Shin SJ; Dodd-Eaton EB; Gao F; Bojadzieva J; Chen J; Kong X; Amos CI; Ning J; Strong LC; Wang W
    Cancer Res; 2020 Jan; 80(2):347-353. PubMed ID: 31719099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating
    Peng G; Bojadzieva J; Ballinger ML; Li J; Blackford AL; Mai PL; Savage SA; Thomas DM; Strong LC; Wang W
    Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):837-844. PubMed ID: 28137790
    [No Abstract]   [Full Text] [Related]  

  • 4. Bayesian estimation of a semiparametric recurrent event model with applications to the penetrance estimation of multiple primary cancers in Li-Fraumeni syndrome.
    Shin SJ; Li J; Ning J; Bojadzieva J; Strong LC; Wang W
    Biostatistics; 2020 Jul; 21(3):467-482. PubMed ID: 30445420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Risks Associated With
    Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB
    JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
    Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
    Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
    Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
    Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
    Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
    Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Rare
    Powers J; Pinto EM; Barnoud T; Leung JC; Martynyuk T; Kossenkov AV; Philips AH; Desai H; Hausler R; Kelly G; Le AN; Li MM; MacFarland SP; Pyle LC; Zelley K; Nathanson KL; Domchek SM; Slavin TP; Weitzel JN; Stopfer JE; Garber JE; Joseph V; Offit K; Dolinsky JS; Gutierrez S; McGoldrick K; Couch FJ; Levin B; Edelman MC; Levy CF; Spunt SL; Kriwacki RW; Zambetti GP; Ribeiro RC; Murphy ME; Maxwell KN
    Cancer Res; 2020 Sep; 80(17):3732-3744. PubMed ID: 32675277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Predicted Effects of
    Liu Y; Axell O; van Leeuwen T; Konrat R; Kharaziha P; Larsson C; Wright APH; Bajalica-Lagercrantz S
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation sequencing is informing phenotype: a TP53 example.
    O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
    Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome.
    Gao F; Pan X; Dodd-Eaton EB; Recio CV; Montierth MD; Bojadzieva J; Mai PL; Zelley K; Johnson VE; Braun D; Nichols KE; Garber JE; Savage SA; Strong LC; Wang W
    Genome Res; 2020 Aug; 30(8):1170-1180. PubMed ID: 32817165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Management of
    Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
    South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.
    Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P
    Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
    Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.
    Macaulay S; Goodyear QC; Kruger M; Chen W; Essop F; Krause A
    Fam Cancer; 2018 Oct; 17(4):607-613. PubMed ID: 29392648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.